Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer

Pharmacogenomics

Volumn 15, Issue 3, 2014, Pages 329-337

  Khrunin, Andrey V ^a   Khokhrin, Denis V ^a   Moisseev, Alexey A ^b   Gorbunova, Vera A ^c   Limborska, Svetlana A ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Russian Federation)

^b Research Medical Centre   (Russian Federation)

^c N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

Author keywords

cisplatin; ovarian cancer; pharmacogenomics

Indexed keywords

ADULT; AGED; BIOMARKERS, PHARMACOLOGICAL; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; METABOLIC DETOXICATION, DRUG; MIDDLE AGED; OVARIAN NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84894440389     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.237     Document Type: Article

References (34)

1. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 7(8), 573-584 (2007).
2. Muggia F. Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecol. Oncol. 112(1), 275-281 (2009).
3. Hogberg T. Chemotherapy: current drugs still have potential in advanced ovarian cancer. Nat. Rev. Clin. Oncol. 7(4), 191-193 (2010).
4. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev. 33(1), 9-23 (2007).
5. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N. Engl. J. Med. 348(6), 538-548 (2003).
6. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 57, 119-137 (2006).
7. Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol. Rev. 63(2), 437-459 (2011).
8. Shimoyama S. Pharmacogenetics of fluoropyrimidine and cisplatin. A future application to gastric cancer treatment. J. Gastroenterol. Hepatol. 24(6), 970-981 (2009).
9. Marsh S. Pharmacogenomics of taxane/platinum therapy in ovarian cancer. Int. J. Gynecol. Cancer. 19(Suppl. 2), 30-34 (2009).
10. Yu W, Gwinn M, Clyne M, Yesupriya A, Khoury MJ. A navigator for human genome epidemiology. Nat. Genet. 40(2), 124-125 (2008).
11. Jung Y, Lippard SJ. Direct cellular responses to platinum-induced DNA damage. Chem. Rev. 107(5), 1387-1407 (2007).
12. Milligan BG. Total DNA isolation. In: Molecular Genetic Analysis of Populations. Hoelzel AR (Ed.). Oxford University Press, London, UK, 29-60 (1998).
13. Khrunin AV, Moisseev A, Gorbunova V, Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J. 10(1), 54-61 (2010).
14. Landi S, Gemignani F, Gioia-Patricola L, Chabrier A, Canzian F. Evaluation of a microarray for genotyping polymorphisms related to xenobiotic metabolism and DNA repair. Biotechniques 35(4), 816-827 (2003).
15. Kweekel DM, Antonini NF, Nortier JW, Punt CJ, Gelderblom H, Guchelaar HJ. Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array. Br. J. Cancer 101(2), 357-362 (2009).
16. Liu K, Muse SV. PowerMarker: an integrated analysis environment for genetic marker analysis. Bioinformatics 21(9), 2128-2129 (2005).
17. Dai Z, Papp AC, Wang D, Hampel H, Wolfgang S. Genotyping panel for assessing response to cancer chemotherapy. BMC Med. Genomics 1, 24 (2008).
18. Deeken J. The Affymetrix DMET platform and pharmacogenetics in drug development. Curr. Opin. Mol. Ther. 11(3), 260-268 (2009).
19. Sissung TM, English BC, Venzon D, Figg WD, Deeken JF. Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. Pharmacogenomics 11(1), 89-103 (2010).
20. Ross CJ, Katzov-Eckert H, Dube MP et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat. Genet. 41(12), 1345-1349 (2009).
21. Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur. J. Cancer 40(16), 2445-2451 (2004).
22. Fotoohi AK, Coulthard SA, Albertioni F. Thiopurines: factors influencing toxicity and response. Biochem. Pharmacol. 79(9), 1211-1220 (2010).
23. Dinkova-Kostova AT, Talalay P. NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch. Biochem. Biophys. 501(1), 116-123 (2010).
24. Fagerholm R, Hofstetter B, Tommiska J et al. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat. Genet. 40(7), 844-853 (2008).
25. Kolesar JM, Dahlberg SE, Marsh S et al. The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer. Oncol. Rep. 25(6), 1765-1772 (2011).
26. Cederbaum AI. Alcohol metabolism. Clin. Liver Dis. 16(4), 667-685 (2012).
27. Xue Y, Wang M, Zhong D et al. ADH1C Ile350 Val polymorphism and cancer risk: evidence from 35 case-control studies. PLoS ONE 7(5), e37227 (2012).
28. Chang JS, Straif K, Guha N. The role of alcohol dehydrogenase genes in head and neck cancers: a systematic review and meta-analysis of ADH1B and ADH1C. Mutagenesis 27(3), 275-286 (2012).
29. Markkanen E, Dorn J, Hübscher U. MUTYH DNA glycosylase: the rationale for removing undamaged bases from the DNA. Front. Genet. 4, 18 (2013).
30. Jansson K, Alao JP, Viktorsson K, Warringer J, Lewensohn R, Sunnerhagen P. A role for Myh1 in DNA repair after treatment with strand-breaking and crosslinking chemotherapeutic agents. Environ. Mol. Mutagen. 54(5), 327-337 (2013).
31. Decker M, Arand M, Cronin A. Mammalian epoxide hydrolases in xenobiotic metabolism and signalling. Arch. Toxicol. 83(4), 297-318 (2009).
32. Parrish AR, Chen G, Burghardt RC, Watanabe T, Morisseau C, Hammock BD. Attenuation of cisplatin nephrotoxicity by inhibition of soluble epoxide hydrolase. Cell Biol. Toxicol. 25(3), 217-225 (2009).
33. Liu Y, Webb HK, Fukushima H et al. Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor kB signaling. J. Pharmacol. Exp. Ther. 341(3), 725-734 (2012).
34. Elkiran T, Harputluoglu H, Yasar U et al. Differential alteration of drug-metabolizing enzyme activities after cyclophosphamide/adriamycin administration in breast cancer patients. Methods Find. Exp. Clin. Pharmacol. 29(1), 27-32 (2007).